Intech Investment Management LLC Has $3.03 Million Stock Position in Collegium Pharmaceutical, Inc. $COLL

Intech Investment Management LLC lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 21.7% in the 3rd quarter, Holdings Channel reports. The firm owned 86,709 shares of the specialty pharmaceutical company’s stock after selling 23,966 shares during the quarter. Intech Investment Management LLC’s holdings in Collegium Pharmaceutical were worth $3,034,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Illinois Municipal Retirement Fund raised its holdings in Collegium Pharmaceutical by 1.6% during the third quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock valued at $605,000 after buying an additional 278 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Collegium Pharmaceutical by 67.0% during the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 350 shares during the last quarter. Assetmark Inc. raised its stake in shares of Collegium Pharmaceutical by 8.4% in the 3rd quarter. Assetmark Inc. now owns 4,551 shares of the specialty pharmaceutical company’s stock valued at $159,000 after acquiring an additional 352 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Collegium Pharmaceutical by 1.4% in the 2nd quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company’s stock worth $863,000 after purchasing an additional 409 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in Collegium Pharmaceutical by 0.6% in the 2nd quarter. Legal & General Group Plc now owns 89,829 shares of the specialty pharmaceutical company’s stock worth $2,656,000 after purchasing an additional 531 shares during the last quarter.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares of the company’s stock, valued at $2,475,141.87. This represents a 6.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the sale, the executive vice president directly owned 103,613 shares in the company, valued at $4,991,038.21. The trade was a 14.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.51% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on COLL. Barclays lowered their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Needham & Company LLC dropped their price objective on Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Collegium Pharmaceutical Price Performance

NASDAQ:COLL opened at $41.60 on Tuesday. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.57 and a quick ratio of 1.48. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $50.79. The company has a fifty day moving average price of $46.36 and a 200 day moving average price of $42.12. The stock has a market cap of $1.32 billion, a P/E ratio of 24.33 and a beta of 0.67.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The company had revenue of $205.45 million for the quarter, compared to the consensus estimate of $206.36 million. During the same quarter in the previous year, the firm posted $1.77 EPS. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.